In the phase 2 study, ITI 007 reduced negative symptoms about 2x as well as placebo, but that’s still not a huge amount. It might have some positive effect though.
In that same phase 2 study, risperidone only improved the PANSS scores of participants by 13.4 points … you don’t always get consistency, part of why clinical trials are so hard.
ITI 007 also might have some antidepressant effects.
I think we’ll know more after they complete the ongoing trials, but it seems like it may be more tolerable, at least for some, and have some additional benefits, at least for some.
It still has side effects though. Just not (it appears) EPS, weight gain, prolactin increase or blood sugar increase.